| Code | CSB-RA011661MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Comekibart, targeting the interleukin-4 receptor (IL4R). IL4R is a type I transmembrane protein that serves as a critical component of both the IL-4 and IL-13 receptor complexes, playing a central role in type 2 immune responses. By binding IL-4 and IL-13, IL4R initiates signaling cascades that drive allergic inflammation, IgE production, and Th2 cell differentiation. Dysregulated IL4R signaling is implicated in various atopic conditions including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyposis.
Comekibart is a therapeutic monoclonal antibody designed to block IL4R, thereby inhibiting both IL-4 and IL-13 signaling pathways. This biosimilar antibody provides researchers with a valuable tool for investigating IL4R-mediated mechanisms in type 2 inflammation, exploring therapeutic interventions for allergic and inflammatory diseases, and conducting preclinical studies related to IL-4/IL-13 pathway modulation. The antibody supports various research applications in immunology, inflammation biology, and translational medicine.
There are currently no reviews for this product.